New drug combo shows promise for Tough-to-Treat bile duct cancer
NCT ID NCT03044587
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested a new chemotherapy combination (Nal-IRI with 5-FU and leucovorin) against a standard treatment (gemcitabine plus cisplatin) in 93 people with advanced biliary tract cancer that could not be removed by surgery. The study aimed to see which approach better controls tumor growth and improves survival. Results will help determine if this new combo deserves further study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Nal-IRI (a chemotherapy drug) combined with 5-fluorouracil and leucovorin
- What this could lead to
- If successful, this could provide a new chemotherapy option for people with advanced biliary tract cancer who cannot have surgery.
- What could go wrong
- This is an early phase 2 trial with a small number of participants, so results may not confirm effectiveness. Chemotherapy can cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Universitätsklinikum Ulm
Ulm, 89081, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?
- 3D MRI scan may predict liver cancer treatment success
- New drug cocktail aims to outperform standard immunotherapy in bile duct cancer
- New scan could spot hidden cancer left behind after liver surgery